Life Molecular Imaging Secures Funding from the Alzheimer's Drug Discovery Foundation (ADDF) to Further Investigate [18F]F-DED PET in Alzheimer's Neuroinflammation
Joining forces to accelerate development and to create a potential new option for Neuroinflammation Imaging
BERLIN and BOSTON, May 20, 2025 /PRNewswire/ -- Life Molecular Imaging has received an investment from the Alzheimer's Drug Discovery Foundation (ADDF) to advance significant research in Alzheimer's disease (AD). The $2.16 million investment, spanning three years, will fuel the development of [18F]F‑DED, an investigational F18-labeled PET imaging agent designed to target monoamine oxidase B (MAO-B), a key enzyme linked to neuroinflammation.
This ambitious research initiative is a collaborative effort with two world-class institutions, including the University Hospital of Ludwig-Maximilian University (LMU; Munich, Germany) and the Barcelona Beta Brain Research Center (BBRC, Spain), with experts in neurology, nuclear medicine, psychiatry, and stroke and dementia research.
It is anticipated that using [18F]F-DED PET imaging during this project has the potential to provide critical insights into both sporadic and genetically predisposed AD patients, bridging the gap on the contribution of neuroinflammation between early and late stages of the disease.
Until now, PET imaging of neuroinflammation has faced challenges due to genetic polymorphisms affecting ligand binding, leading to inconsistent results.
'This new research, supported by the prestigious ADDF funding, provides a unique opportunity to investigate the spatial and temporal dynamics of neuroinflammation and its association with established biomarkers,' said Andrew Stephens, Chief Medical Officer at LMI.
'Neuroinflammation could be a potential key driver in the spread of tau pathology to the cortex in Alzheimer's disease. Leveraging PET imaging to explore its role presents a unique opportunity to deepen our understanding of disease progression,' added Matthias Brendel, Professor for Nuclear Medicine at LMU.
Gemma Salvadó Blasco, Group Leader of Neuroimaging Research BBRC, echoed this enthusiasm: 'By combining data from diverse Alzheimer's disease cohorts, we aim to unravel the complexities of disease progression. We're thrilled to embark on this exciting journey.'
'PET-Imaging tools provide important insights into understanding Alzheimer's disease and other neurodegenerative disorders and are integrated now into clinical care,' says Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF. 'New imaging tools exploring neuroinflammation may offer a non-invasive approach to visualize astrocyte activity alongside established biomarkers to further examine the relationship between inflammation and Alzheimer's. If successful, this innovative approach will help deepen our understanding of the underlying disease.'
About
Neuroinflammation represents a key pathologic mechanism in many neurodegenerative diseases, including AD, movement disorders and multiple sclerosis. In the brain it can be mediated by reactive astrocytes (astrogliosis), which show increased activity of the enzyme monoamine oxidase B (MAO-B). The PET tracer [18F]F-DED is a deuterated deprenyl derivative that was designed to preferentially bind to areas with increased MAO-B activity (1,2).
About Life Molecular Imaging (LMI)
Life Molecular Imaging (LMI) is an international radiopharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit https://life-mi.com.
About Life Healthcare Group
Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 40 years' experience in the South African private healthcare sector, and currently operates 64 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, oncology, diagnostic and molecular imaging and health risk management services which include occupational health and wellness services. The Group also owns Life Molecular Imaging, a radiopharmaceutical business dedicated to developing and globally commercializing innovative molecular imaging agents for use in PET-CT diagnostics to detect specific diseases. Visit: https://www.lifehealthcare.co.za/.
About The Alzheimer's Drug Discovery Foundation (ADDF)
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: http://www.alzdiscovery.org/.
References
1. Nag S, Fazio P, Lehmann L, et al. In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl. J Nucl Med. 2016;57(2):315-320. doi:10.2967/jnumed.115.161083
2. Ballweg A, Klaus C, Vogler L, et al. [18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data. J Neuroinflammation. 2023;20(1):68. Published 2023 Mar 11. doi:10.1186/s12974-023-02749-2
For media queries
Brittany Hahn | Marketing Communications Manager | Life Molecular Imaging
Tel: +1.484.735.2840 | [email protected]
For scientific information, please contact: Dr. Gérard N Bischof, PD | Scientific Project Manager | Life
Molecular Imaging| [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/life-molecular-imaging-secures-funding-from-the-alzheimers-drug-discovery-foundation-addf-to-further-investigate-18ff-ded-pet-in-alzheimers-neuroinflammation-302459645.html
SOURCE Life Molecular Imaging
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
3 hours ago
- Entrepreneur
Sustainability in Business: Lessons from the Food and Beverage Sector
The future of sustainable business in the Middle East lies in partnership — with suppliers, regulators, and communities alike. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur Middle East, an international franchise of Entrepreneur Media. In today's business landscape, sustainability has evolved from a corporate buzzword into a fundamental expectation. Across the Middle East, where economic growth and urban development are accelerating, businesses are re-evaluating how they operate — not only to remain competitive, but to be responsible stewards of the environment. The food and beverage (F&B) sector is particularly well-positioned to lead this change. With high energy demands, supply chain complexities, and significant packaging and food waste, the industry carries both a large environmental footprint and a powerful opportunity for impact. Drawing from experiences within one of the world's largest quick-service restaurant brands, this article explores how sustainability practices can be integrated into core business operations in a region as diverse and complex as the Middle East. The focus is not on promotion, but on practical strategies and challenges — and how companies can begin or deepen their journey toward environmental responsibility. Why Local Context Matters While global sustainability frameworks offer a helpful foundation, regional adaptation is essential. In the Middle East, climate, infrastructure, and policy differ widely between countries — from water scarcity in the Gulf to rapidly urbanising centres in the Levant. Businesses must tailor their strategies to reflect these realities. For example, energy use is a key area of focus, especially in hot climates where cooling systems are essential. Understanding and optimising HVAC (heating, ventilation, and air conditioning) systems is not just a technical detail — it's a business imperative. Similarly, innovations like low proximity hoods in kitchens can reduce overall energy consumption significantly when implemented at scale. Investments in energy-efficient equipment, such as LED lighting and high-efficiency refrigeration, might seem minor in isolation. Yet, when adopted consistently across locations, they contribute meaningfully to both environmental impact and operational cost savings. Three Core Pillars of Sustainable Practice Sustainability efforts in the F&B industry often centre around three main pillars: environmental responsibility, responsible sourcing, and waste reduction. Each presents its own challenges and opportunities in the Middle Eastern context. 1. Environmental Responsibility Adopting energy-saving technologies, exploring renewable energy sources like solar (particularly in high-insolation regions such as the UAE and Saudi Arabia), and conserving water through low-flow fixtures and efficient cleaning practices are becoming standard in many progressive operations. 2. Responsible Sourcing Local procurement reduces emissions tied to transport while supporting regional economies. Businesses are increasingly working with suppliers who meet standards not only for quality, but also for ethical labour practices and environmental impact. Rigorous auditing and supply chain transparency play a key role in maintaining accountability. 3. Waste Reduction and Recycling The F&B sector produces large volumes of waste — food scraps, packaging, and single-use materials among them. Inventory control systems, food donation programs, and in-store recycling can help mitigate this. In some regions, composting is also gaining traction, despite infrastructure challenges. Challenges and Opportunities in Implementation Implementing sustainability measures in the Middle East comes with complexities. Regulatory environments vary, and upfront costs for green technologies can be a barrier. Infrastructure for recycling and renewable energy may be inconsistent across markets. Yet, these challenges also open the door for innovation. Businesses willing to invest in energy solutions or engage with local suppliers to build capacity often find long-term gains — both financially and reputationally. Moreover, as consumer awareness around sustainability increases, demand is growing for businesses that can demonstrate real action, not just intention. Looking Ahead: A Call to Action Sustainability is not a destination but a continuous process. As governments across the region introduce more robust environmental policies and incentives, there is growing momentum for businesses to step up. The future of sustainable business in the Middle East lies in partnership — with suppliers, regulators, and communities alike. For the F&B industry in particular, every decision — from equipment to packaging, sourcing to staff training — holds the potential to shape a more resilient, responsible business model. The companies that succeed will be those that not only adapt to change but help lead it.
Yahoo
8 hours ago
- Yahoo
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting. Further details have been posted on the corporate website The article in The Lancet was titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial". Full article available at: The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)". Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, "The CT041-ST-01 trial represents the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients' survival, and ultimately pursue potential cures." Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team's years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world's first commercially available CAR-T product for solid tumors, bringing benefits to patients." About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics
Yahoo
9 hours ago
- Yahoo
Can adults grow new brain cells?
When you buy through links on our articles, Future and its syndication partners may earn a commission. The developing human brain gains billions of neurons while in the womb, and tacks on some more during childhood. For most of the 20th century, the conventional wisdom was that the brain cells grown before adulthood would be the only ones we would have for the rest of our lives. But over the past few decades, more and more research is challenging that belief. So is it actually possible for adults to grow neurons? While some experts believe there's strong evidence that we can gain brain cells after childhood, others are still skeptical of this notion. The process of creating new brain cells is called neurogenesis. Researchers first observed neurogenesis after birth in lab animals of various ages, including mice, rats and songbirds. In adult mice, they found new neurons growing in parts of the brain collectively called the subventricular zone, an area closely linked with sense of smell, as well as in the hippocampus, a structure that's central to memory. Researchers think that neurogenesis in these brain regions is important for plasticity, or the brain's ability to adapt and change over time. Plasticity underlies the ability to learn and form memories, for instance. In mice, it's clear that lifestyle factors such as living in a stimulating environment and exercising can promote the growth of new neurons. Conversely, in mouse models of diseases like Alzheimer's, neurogenesis is hampered. What's still up for debate is whether these findings extend beyond mice and other lab animals. "Most of our knowledge about adult neurogenesis came from studies in animal models," Hongjun Song, a professor of neuroscience at the University of Pennsylvania Perelman School of Medicine, told Live Science in an email. "Whether such knowledge can be directly translated to human studies is a challenge." That's because many of the studies that have established the existence of adult neurogenesis in animals used methods that aren't possible in human studies, such as injecting radioactive tracer molecules into the brain. These methods enable scientists to visualize if and where new neurons are growing, but the tracers themselves can be toxic. These methods also require dissecting the brain after the animal has been euthanized. "Unfortunately, there is no way to measure neurogenesis in the living person yet," Gerd Kempermann, a professor of genomics of regeneration at the Center for Regenerative Therapies in Dresden, Germany, told Live Science in an email. Related: Is there really a difference between male and female brains? Emerging science is revealing the answer. There are, however, some rare cases in which scientists have been able to apply similar methods to track neurogenesis in humans. For example, the radioactive tracer molecules used in animal neurogenesis studies are also sometimes used by doctors to track tumor growth in patients with brain cancer. While these radioactive tracer molecules are too toxic to give to healthy people, their benefits outweigh their risks in patients who already have cancer. Scientists behind a 1998 study published in the journal Nature Medicine used this approach and analyzed the brains of cancer patients after their deaths. They reported that, in addition to flagging cancer cells, the tracer molecules had marked new neurons in the hippocampus. This finding suggested that humans could grow new neurons well into adulthood, given the patients were 57 to 72 years old. Later, a 2013 study in the journal Cell used a form of radiocarbon dating to look for new neurons in humans. Radiocarbon dating usually determines the age of a sample by comparing the relative proportion of two different forms of carbon, or carbon isotopes, called carbon-14 and carbon-12. But to study neurogenesis in humans, scientists instead looked at carbon-14 concentrations inside the DNA of cells. Their approach took advantage of the fact that there was a spike in carbon-14 levels in the atmosphere caused by nuclear bomb tests in the 1950s and 1960s. People's bodies absorbed this carbon-14 via their diets, and it became incorporated into their DNA. The amount of carbon-14 in a given cell corresponds to the isotope's concentrations in the atmosphere at the time the cell formed, making it possible to roughly pinpoint the "birthday" of that cell — and determine whether it formed after its owner's birth. By analyzing postmortem brain tissue from people ages 19 to 92, this radiocarbon study identified newborn neurons in the adult hippocampus. But while compelling, the study's methods were so complex that the results have never been replicated. That said, there are also more indirect markers of neurogenesis, such as certain proteins that are only present in growing neurons. Using these methods, both Kempermann and other research groups have uncovered additional evidence of newborn neurons in the adult human brain. "There are many different markers that are more or less specific for adult neurogenesis," Kempermann said. "In tissue sections, one can study these markers under the microscope and look for patterns that are consistent with neuronal development." But some researchers aren't convinced by this evidence. Arturo Alvarez-Buylla, a professor of neurological surgery at the University of California, San Francisco, has spent his career studying the growth of new neurons. While he's observed new neurons being formed in children and adolescents, he's found little evidence to support the notion of neurogenesis in adults. Alvarez-Buylla believes there are a number of issues that may lead other researchers to find signs of neurogenesis in adult humans. For example, the chemical markers that some labs use to track new neurons may also show up in other cell types, such as glia, which are cells in the brain that support neurons' function in various ways. This may make it appear that new neurons are growing when they're actually not. He's also skeptical of the use of carbon-14 dating for this purpose, calling it "creative" but arguing that researchers can't confirm that the new cells are neurons, or if there could be other potential reasons for varying carbon-14 levels in cells. But Alvarez-Buylla isn't ruling out the possibility of human adult neurogenesis; he's only saying that — so far — the evidence hasn't convinced him. "I would say that is a rare phenomenon," said Alvarez-Buylla. "If it happens, it's very, very few cells." Kempermann, on the other hand, is a firm believer that people can grow new neurons well into adulthood. "The positive reports outnumber the critical papers by far, their take is much wider, and their quality is overall higher." The researchers said that understanding whether adult neurogenesis exists will continue to be a key question for the field of neuroscience. RELATED STORIES —Could we ever retrieve memories from a dead person's brain? —What happens in your brain while you sleep? —How much of your brain do you need to survive? "The question about whether adults can grow new neurons has tremendous implications for the plasticity of the adult brain," Song said. If new neurons can be grown and integrated into the brain, he explained, those mechanisms could form the basis for new therapies for a variety of conditions, including brain injuries and neurodegenerative disorders. Alvarez-Buylla said that even if he doesn't believe neurogenesis happens frequently in adults, it may nonetheless be possible to harness the mechanisms used by animals to grow new neurons for human therapies. "The whole idea that it can happen opens a huge door for repair," he said. "I hope that we can keep our plasticity open to things going either way."
